Barclays Increases Illumina (NASDAQ:ILMN) Price Target to $145.00

Illumina (NASDAQ:ILMN) had its price objective raised by stock analysts at Barclays from $135.00 to $145.00 in a report released on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the life sciences company’s stock. Barclays‘s price objective points to a potential downside of 4.50% from the stock’s current price.

Several other equities analysts have also commented on the stock. StockNews.com started coverage on shares of Illumina in a report on Thursday, August 29th. They set a “buy” rating on the stock. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Royal Bank of Canada restated an “outperform” rating and set a $252.00 target price on shares of Illumina in a report on Thursday, October 10th. UBS Group lifted their price target on Illumina from $131.00 to $133.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Daiwa America raised Illumina to a “strong-buy” rating in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $162.18.

Illumina Stock Down 2.0 %

ILMN opened at $151.83 on Tuesday. The business’s fifty day simple moving average is $137.27 and its 200 day simple moving average is $123.12. Illumina has a 52 week low of $89.00 and a 52 week high of $156.66. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The stock has a market cap of $24.19 billion, a PE ratio of -15.24 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 6.36% and a negative net margin of 36.10%. The company’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.33 EPS. As a group, research analysts expect that Illumina will post 3.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

Hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc lifted its holdings in shares of Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new position in Illumina during the second quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of Illumina in the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new stake in Illumina during the second quarter valued at $63,000. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.